aap Implantate AG, a medical technology company listed in the Prime Standard segment of the Frankfurt Stock Exchange, was able, according to interim figures, to boost sales revenue by 5 percent on the year to EUR 25.5 million in the first nine months of its 2009 financial year.

By signing at the end of August, in addition to regular sales of implants and biomaterials, an exclusive license agreement worth EUR 3 million on the use of intellectual property relating to a medical aesthetics product and by selling a bone graft substitute patent in the dental sector worth EUR 1 million, aap is able to report for the third quarter of 2009 EUR 10.8 million, the highest quarterly sales figure in its corporate history.

Both transactions are designed to have not just a one-off effect but to generate further aap growth in the years ahead. By means of their immediate effect on the earnings position they and the results of the biomaterials and implant business jointly underpin the EBITDA forecast of between EUR 5 million and EUR 7 million in fiscal 2009.

Along with aap’s focus on the Ortho/Trauma/Spine lines of business and its consistent concentration on customers, costs and cash, both of which have already achieved first pleasing results, enlargement and exploitation of the strategic IP portfolio is a further key element in the company’s strategic alignment. Exploitation of intellectual property mainly takes the form of joint research and development projects with global partner companies or licensing out the resulting products. The Management Board also anticipates from this line of business positive contributions toward operating income.

aap plans to publish its Q3 2009 report in full on November 6, 2009.